|
|
| |
| Articles
by
Cassandra Szoeke |
Total Records (
2 ) for
Cassandra Szoeke |
|
 |
| |
|
| |
Kathryn A. Ellis
,
Christopher C. Rowe
,
Victor L. Villemagne
,
Ralph N. Martins
,
Colin L. Masters
,
Olivier Salvado
,
Cassandra Szoeke
and
David Ames
|
| |
The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer’s disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer’s Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B (11C-PiB) positron emission tomography (PET) acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data. Differences to ADNI include assessment every 18-months, imaging in 25% (magnetic resonance imaging, 11C-PiB PET but no fluorodeoxyglucose PET), more comprehensive neuropsychological testing, and detailed collection of diet and lifestyle data. AIBL has completed the first 18-month follow-up and is making imaging and clinical data available through the ADNI website. Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle. |
|
| |
|
| |
Maria C. Carrillo
,
Christopher C. Rowe
,
Cassandra Szoeke
,
Colin L. Masters
,
David Ames
,
Tim O’Meara
,
S. Lance Macaulay
,
Andrew Milner
,
Kathryn A. Ellis
,
Paul Maruff
,
Stephanie R. Rainey- Smith
,
Ralph N. Martins
,
Lisa J. Bain
and
Richard J. Head
|
| |
Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide. |
|
|
|
|
| |
|
